Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis.

Cancer Med · 2023 · PMC10587960 · PMID 37737544

Europe PMC DOI

hedged sentence

0.2391

closest p · 4.8× alpha

0.2391

boldest claim

The sentences

did not reach statistical significancep = 0.2391not close (p > 0.1)

The pooled ratio of HRs for PFS between the Asian and non‐Asian subgroups ( m = 12) did not reach statistical significance (HR: 0.93; 95% CI: 0.82–1.07; p = 0.2391; chi‐square Q test χ 2 = 7.37, p = 0.77; I 2 ≈ 0%; Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.